Randomized trial of daily high-dose vitamin D 3 in patients with RRMS receiving subcutaneous interferon β-1a
Open Access
- 12 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 93 (20), e1906-e1916
- https://doi.org/10.1212/wnl.0000000000008445
Abstract
Objective In the phase II, randomized, double-blind, placebo-controlled Supplementation of Vigantol Oil versus Placebo Add-on in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Receiving Rebif Treatment (SOLAR) study (NCT01285401), we assessed the efficacy and safety of add-on vitamin D3 in patients with RRMS. Methods Eligible patients with RRMS treated with SC interferon-β-1a (IFN-β-1a) 44 μg 3 times weekly and serum 25(OH)D levels 3 14,007 IU/d (n = 113). The revised primary outcome was the proportion of patients with no evidence of disease activity (NEDA-3) at week 48. Results At 48 weeks, 36.3% of patients who received high-dose vitamin D3 had NEDA-3, without a statistically significant difference in NEDA-3 status between groups (placebo 35.3%; odds ratio 0.93; 95% confidence interval [CI] 0.53–1.63; p = 0.80). Compared with placebo, the high-dose vitamin D3 group had better MRI outcomes for combined unique active lesions (incidence rate ratio 0.68; 95% CI 0.52–0.89; p = 0.0045) and change from baseline in total volume of T2 lesions (difference in mean ranks: −0.074; p = 0.035). Conclusions SOLAR did not establish a benefit for high-dose vitamin D3 as add-on to IFN-β-1a, based on the primary outcome of NEDA-3, but findings from exploratory outcomes suggest protective effects on development of new MRI lesions in patients with RRMS. Clinicaltrials.gov identifier NCT01285401. Classification of evidence This study provides Class II evidence that for patients with RRMS treated with SC IFN-β-1a, 48 weeks of cholecalciferol supplementation did not promote NEDA-3 status.This publication has 30 references indexed in Scilit:
- Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosisNeurology, 2016
- Effect of vitamin D on MS activity by disease-modifying therapy classNeurology Neuroimmunology & Neuroinflammation, 2015
- Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1bJAMA Neurology, 2015
- Vitamin D in clinically isolated syndrome: evidence for possible neuroprotectionEuropean Journal of Neurology, 2015
- Vitamin D as an Early Predictor of Multiple Sclerosis Activity and ProgressionJAMA Neurology, 2014
- MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trialsNature Reviews Neurology, 2011
- Effects of vitamin D on the peripheral adaptive immune system: A reviewAutoimmunity Reviews, 2011
- A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosisNeurology, 2011
- Vitamin D: criteria for safety and efficacyNutrition Reviews, 2008
- Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin DMedical Hypotheses, 1986